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ABSTRACT
Brucellosis and pseudorabies lead to abortion in pregnant sows and are perpetuated by
feral swine reservoirs. A multivalent oral vaccine for these diseases would improve vaccination
and eradication programs worldwide. Previous studies have shown that the rough attenuated
Brucella strains RB51 and VTRS1, when administered subcutaneously to swine, stimulate host
immune responses, transiently colonize tissues, and provide partial protection against virulent B.
suis infection in pregnant sows. A plasmid encoding for the pseudorabies virus glycoprotein D
(PRV gD) has also been added to these strains as part of this project. This study evaluates the
use of these strains as oral vaccines for swine brucellosis and investigates the ability of these
vaccines to colonize lymph nodes and stimulate the production of antibodies against rough
Brucella antigens and PRV gD. Orally administered VTRS1 stimulated a higher immune
response than RB51 in a shorter period of time, transiently colonized lymph nodes, and did not
lead to the production of anti-O-polysaccharide (OPS) antibodies that interfere with brucellosis
diagnostic tests. Both RB51 and VTRS1 provided substantial litter protection in orally
vaccinated sows challenged with virulent B. suis; however, VTRS1, unlike RB51, also provided
partial protection in the sow. These studies support the use of orally administered VTRS1 as an
efficacious vaccine for swine brucellosis. The addition of a plasmid encoding for PRV gD to
these strains created the multivalent vaccines RB51+gD and VTRS1+gD. Compared to the
above strains, the addition of the plasmid did not alter immune response stimulation to rough
Brucella antigens and these vaccines were safe when administered to pregnant sows. Swine
vaccinated with RB51+gD or VTRS1+gD exhibited low immune responses to the gD antigen
and delayed tissue colonization by the vaccine strains. It was found that plasmid addition slowed
the growth of the vaccine strains in the laboratory, which may account for the suppressed tissue
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colonization and immune responses to the PRV gD antigen in swine. Further studies are
necessary to evaluate the use of these strains as multivalent vaccines for brucellosis and
pseudorabies in swine.
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CHAPTER 1: INTRODUCTION
Following an overview of the research problem and a review of the literature, the
generation of the multivalent vaccine strains VTRS1+gD and RB51+gD via the addition of a
plasmid encoding for the pseudorabies virus glycoprotein D to brucellosis vaccine strains B.
abortus strain RB51 and B. suis strain VTRS1 will be described. Serological responses to orally
administered VTRS1 and RB51 and the colonization of orally and subcutaneously administered
VTRS1 in sexually immature swine will be characterized and compared to previously collected
data. The transformed strains VTRS1+gD and RB51+gD will also be discussed in terms of their
stimulation of the immune response and tissue colonization and pathogenicity in pregnant sows
when administered orally or subcutaneously to swine. Finally, the protection of VTRS1 and
RB51 against virulent B. suis challenge in sows will be evaluated.
Overview of the Research Problem
Brucella suis and pseudorabies virus (PRV) are perpetuated by feral swine reservoirs that
readily transmit these diseases to domestic herds (Hahn et al 1997, Dees 1999). The presence of
over two million feral swine in the United States alone complicates vaccination and eradication
programs, including routine surveillance and culling of infected animals (Conger 1999).
Therefore, an orally administrable, multivalent vaccine for both B. suis and PRV would be ideal
for this target population.
Brucella suis infection in swine can result in abortion and both male and female infertility
(Deyoe and Manthei 1975). There is currently no commercially available vaccine for swine
brucellosis; however, the attenuated strains RB51 and VTRS1 have been shown by previous
studies to provide protection against virulent B. suis infection when administered subcutaneously
and do not interfere with current diagnostic tests (Hagius et al 1995, Hagius et al 2001).
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Pseudorabies virus, like B. suis, may also cause abortion, stillborn, macerated, or weak piglets,
and while a commercial vaccine is available it is often not utilized due to difficulty in
distinguishing vaccinates from infected animals during routine screening (Gustafson 1981). The
use of PRV glycoprotein D (gD) as a potential subunit vaccine has been shown to protect mice
against virulent PRV challenge when administered via a variety of vectors (Ishii et al 1988,
Marchioli et al 1987, Shiau et al 2001), and vaccination of swine with PRV gD DNA provided
partial protection against virulent challenge (Haagmans et al 1999).
The use of gD administered via VTRS1 or RB51 would ideally provide protection against
both pseudorabies and swine brucellosis. Oral administration of these multivalent vaccines
would allow for more widespread vaccination of the feral swine population without interference
with sero-diagnostic tests.
Research Objectives
This report describes the work performed in order to accomplish the following research
objectives:
1. Evaluation of two potential vaccine strains for B. suis, RB51 and VTRS1, in terms of
tissue colonization, generation of immune responses, and protection against virulent
B. suis challenge when administered orally to swine.
2. Transformation of RB51 and VTRS1 with a plasmid encoding for the PRV gD,
creating potential multivalent vaccine strains RB51+gD and VTRS1+gD. Evaluation
of these transformed strains in terms of tissue colonization, fetal pathogenesis, and
generation of immune responses in swine when administered either subcutaneously or
orally.
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CHAPTER 2: REVIEW OF THE LITERATURE
Brucella Species
The genus Brucella consists of Gram-negative, facultative intracellular bacteria that
reside primarily within macrophages. These bacteria are non-acid-fast, non-motile, non-sporeforming, short aerobic rods which often require increased carbon dioxide tension for growth,
with colonies rarely appearing within the first forty-eight hours of incubation. There are
currently six defined species that manifest themselves in a variety of hosts and are characterized
based on dye and host susceptibilities. Brucella abortus is primarily responsible for infecting
cattle and North American wild ruminants while B. melitensis infects goats and sheep, B. ovis
infects sheep, B. suis infects swine and reindeer, B. canis infects dogs, and B. neotomae infects
the desert wood rat (Timony et al 1988).
Of the six defined Brucella species only four are zoonotic in nature: B. melitensis, B. suis,
B. abortus, and B. canis. Human infection results in undulant fever, a flu-like illness with
symptoms of weakness, night sweats, and a cycling fever (Timony et al 1988). Due to the ability
of these agents to illicit debilitating disease in humans and potentially significant damage to
livestock and food supplies, Brucella species are considered biological weapons of mass
destruction (Horn and Breeze 1999, Kortepeter and Parker 1999). These biological warfare
agents are listed as overlap select biological agents by the Department of Health and Human
Services (HHS) (42 CFR 73; December 13, 2002) and the United States Department of
Agriculture (USDA) (9 CFR 121 and 7 CFR 331; December 13, 2002). Of these select agents,
the complete genomic sequences of B. melitensis and B. suis have been published (DelVecchio et
al 2002, Paulsen et al 2002).
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The outer membranes of brucellae are like that of other Gram-negative bacteria in that the
outermost layer is lipopolysaccharide (LPS) (Cherwonogrodzky et al 1990). Brucella species
which are smooth contain an LPS in which O-polysaccharide (OPS) molecules are attached to
lipid A via core oligosaccharides. These species include B. melitensis, B. suis, B. abortus, and B.
neotomae (Cherwonodrodzky et al 1990, Timony et al 1988).

In contrast, rough Brucella

species, B. ovis and B. canis, lack OPS (Cherwonogrodzky et al 1990). When OPS is removed
from smooth LPS Brucella strains there is a significant decrease in virulence (Kreutzer and
Robertson 1979); however, B. canis and B. ovis, which are both naturally occurring rough
Brucella species are virulent in their natural hosts (Timony et al 1988).
Two antigens, A and M, are associated with the OPS of smooth Brucella species. First
isolated from B. abortus, the A antigen consists of linear unbranched homopolymers of 1,2linked 4,6-dideoxy-4-formamido-α-D-mannopyranosyl units (perosamine), whereas the M
antigen isolated from B. melitensis OPS consists of a linear unbranched chain with
pentasaccharide perosamine repeating units containing one 1,3-linked and four 1,2-linked
residues (Bundle et al 1987). The presence of the A or M antigen is used to distinguish between
species and biovars of Brucella; however, in some strains these antigens appear simultaneously
or may be absent altogether (Timony et al 1988). Brucella OPS is an immunogenic antigen,
provoking the initiation of the host’s humoral immune response (Hurvell 1973) and thus the
formation of anti-OPS antibodies. Serological diagnosis of infected animals is based on the
presence or absence of anti-OPS antibodies. Currently available serological tests for brucellosis
are the Rose Bengal test, Plate Agglutination test, Card test, Standard Tube Agglutination test,
Complement Fixation test, Milk Ring test, Coombs test, Rivanol test, and Enzyme-linked
Immunosorbant Assay (ELISA) (MacMillan 1990, Timony et al 1988).
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Brucella suis
In 1914, Jacob Traum first isolated Brucella suis from an aborted piglet found in an
Indiana swine herd (Alton 1990). Since then, five biovars of B. suis have been defined and
characterized based on specific growth requirements such as: utilization of serum, dye
sensitivity, carbon dioxide requirement, hydrogen sulfide production, bacteriophage
susceptibility, and the presence of the A and/or M antigens on the OPS (Meyer 1990). Biovar 1
displays the most classical characteristics of B. suis and is the most prevalent in the United
States. The primary hosts of biovars 1, 2, and 3, are swine. Biovars 1, 2, and 3 are present in
most swine-raising areas of the world, while biovar 4 infects reindeer and caribou in the Arctic
Circle. All but biovar 2 have been associated with undulant fever in humans and are therefore
zoonotic agents. Biovar 5, which is still poorly characterized, is believed to infect only murine
species (Deyoe and Manthei 1975, Manthei 1968, Timony et al 1988).
Swine Brucellosis
Brucella suis causes swine brucellosis, which is manifested by abortion and infertility in
females and males. Swine brucellosis is difficult to diagnose due to the number of asymptomatic
cases, and disease is often not noted until there is a decrease in herd reproduction (Alton 1990).
Abortion is the most common manifestation in females (Deyoe and Manthei 1975); however,
piglets may be delivered healthy, stillborn, mummified, or weak. Mastitis, abscess formation,
and chronic metritis are also common, with the latter being the major cause of infertility in sows
(Alton 1990, Leman et al 1974). Brucellae are shed from the uterus for up to 30 months postparturition, potentially infecting an entire herd (Deyoe and Manthei 1975).
Unlike B. abortus and B. melitensis, B. suis is a venereal disease and boars are
susceptible to infection. In males, swelling and atrophy of the epididymides and unilateral or
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bilateral orchitis are common with persistent genital infection resulting in the shedding of
brucellae in the semen for up to three to four years after infection. Both sexes may experience
lameness and swollen joints (Alton 1990, Deyoe and Manthei 1975, Enright 1990). Spondylitis
results from the localization of brucellae in the lumbar and sacral regions of the vertebrae, and
infection can also result in paralysis in some animals from pressure on the spinal cord due to
necrotic tissue (Timony et al 1988).
The majority of B. suis infections occur via exposure of the alimentary or genital tracts
(Deyoe and Manthei 1975). During ejaculation the boar produces a large amount of semen
which migrates through the cervical folds into the sow’s uterus, making venereal transmission
fairly common (Manthei 1968). The consumption of feed that has been contaminated by urine or
genital excretions could also provide a mode of entry for the organism (Timony et al 1988).
Transmission may also occur via contact with the respiratory tract, conjunctiva, or skin (Deyoe
and Manthei 1975).
The course of infection of B. suis is similar to that of all other Brucella species. The
brucellae first penetrate mucosal membranes, typically the uterine, oral, or nasopharyngeal
mucosa, in order to gain entry into the host. Once passage through mucosal membranes has
occurred, brucellae are able to reside within host macrophages which transport the organism to
draining lymphatics and regional lymph nodes (Enright 1990). As the organism begins to
replicate, local inflammation develops and the lymph nodes become hemorrhagic. Access to the
blood results in bacteremia, which, in the case of B. suis infection, is most persistent during the
first eight weeks following infection, but may persist for years in swine displaying clinical
symptoms (Deyoe and Manthei 1975). The incubation period of B. suis is approximately 10-30
days, after which the pig is considered to be infected (Manthei 1968), and in young piglets often
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a latent infection sets in, impeding diagnosis prior to the immediate post-weaning period (Goode
et al 1952). Swine infected after five months of age, the onset of sexual maturity, are more likely
to develop chronic brucellosis than those infected as suckling or weanling piglets (Manthei et al
1952).
Brucella suis localizes to the reproductive tract, skeletal system, joints, mammary glands,
lymph nodes, spleen, liver, kidneys, bladder, and brain. In the infected sow or gilt, chronic
metritis typically develops which interferes with conception and contributes to the prolonged
shedding of brucellae from the uterus. This also leads to late-gestation abortions, usually
occurring at 65-72 days (Enright 1990, Leman et al 1974).
Vaccine Strains
Live vaccines for brucellosis, in general, provide more complete and lasting immunity
than killed or subcellular vaccines. This is due to their ability to provoke cell-mediated immune
responses which are necessary to clear intracellular bacterial infections such as Brucella (Schurig
et al 2002). An ideal vaccine should be one that is stable; can be easily produced and stored; and
provides lasting immunity. In addition, the vaccine should not induce immune responses that
interfere with diagnostic tests and be non-pathogenic to vaccinated animals and humans handling
the vaccine (Nicoletti 1990). Currently there is no commercially available vaccine for swine
brucellosis, but current research efforts are underway.
Brucella abortus Strain 19. Dr. John M. Buck, a bacteriologist with the Pathological
division of the Bureau of Animal Industry, Washington, D.C., recovered a virulent strain of B.
abortus from the milk of a Jersey cow in June 1923. After passaging and maintaining the culture
at room temperature for one year the organism’s virulence was lost, and B. abortus Strain 19, the
nineteenth stock culture of the series, was tested as a potential vaccine for bovine brucellosis.
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This vaccine was found to be protective for bovine brucellosis and introduced for field usage in
1941. Since then Strain 19 has become the most widely used cattle vaccine for brucellosis
(Graves 1943, Nicoletti 1990). Strain 19, like the smooth strains B. melitensis, B. abortus, and B.
suis, causes undulant fever in humans and therefore extreme care must be taken when handling
this vaccine (Nicoletti 1990).
Strain 19 has proven to be an efficacious bovine vaccine due to its high antigenicity and
low virulence (Lawson 1950, Schurig 2002 et al). Protection in vaccinated pregnant heifers after
virulent B. abortus challenge was greater than 90% when compared to unvaccinated controls
(Confer et al 1985, Nicoletti 1984). Calves administered one dose at approximately six months
of age sustain immunity to virulent B. abortus for five or more pregnancies (McDiarmid 1957).
While Strain 19 is an efficacious vaccine, there are several problems associated with its
use in cattle. The first issue lies within the fact that Strain 19 contains OPS similar to field
strains of B. abortus (Lawson 1950), and vaccination with this strain leads to the production and
persistence of OPS-specific antibodies (Nicoletti 1990). Current serological tests for brucellosis
rely on the presence of these antibodies to distinguish infected from non-infected animals,
therefore making it difficult to differentiate vaccinated from field strain infected cattle during
routine brucellosis screening (Schurig et al 2002). It is estimated that 0.5-15% of Strain 19
vaccinates become persistent reactors to brucellosis diagnostic tests even when they receive a
reduced dose of the vaccine (Alton et al 1980, Beckett and MacDiarmid 1987, Nicoletti 1984). It
is strongly discouraged to use Strain 19 during pregnancy, when the animal is most susceptible to
brucellosis infection, since it may induce abortion in 0.5-2.5% of vaccinates (Beckett and
MacDiarmid 1987, Nicoletti 1990, Schurig et al 2002). While Strain 19 is an efficacious vaccine
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in cattle, swine vaccinated SC with this vaccine were not protected against field exposure to
virulent B. suis (Lindley and Lander 1949).
Brucella suis Strain 2. In an effort to find a vaccine for swine brucellosis, Brucella suis
Strain 2 was tested in China in the late 1970s. This vaccine is a laboratory adapted smooth strain
of B. suis biovar 1 that was attenuated naturally after serial transfer on culture media for years. It
has been shown to be efficacious when administered orally in sheep, goats, cattle, and swine.
Pigs that received two oral doses of Strain 2, two to three months apart, were afforded 75%
protection against conjunctival virulent B. suis infection without persisting antibody titers;
however, no protection was seen when animals were challenged by mating with a boar excreting
B. suis in his semen. This becomes problematic since venereal transmission of B. suis is
common (Nicoletti 1990, Xin 1986). The dose of Strain 2 administered per animal has never
been reported since the live culture was poured into water troughs and individual consumption
was not monitored, and parenteral administration in ruminants resulted in abortion (Xin 1986).
Brucella abortus Strain RB51. Schurig et al serially transferred B. abortus Strain 2308
onto tryptic soy broth agar (TSBA) plates supplemented with rifampin and penicillin. Prior to
each transfer, single colonies displaying rough colony morphology and antibiotic resistance were
isolated, and after a total of 51 transfers the rough attenuated B. abortus Strain RB51 was shown
to be stable in BALB/c mice with no reversion to a smooth phenotype. Colonization
experiments in mice demonstrated a decrease in colony-forming units (CFU)/spleen of the
vaccine over time with no RB51 recovered at four weeks post-inoculation (p.i.). When 1 x 108
CFU of RB51 was inoculated intraperitoneally (IP) in mice seven weeks prior to challenge with
virulent B. abortus Strain 2308, vaccinated mice had decreased numbers of CFU of strain 2308
in their spleens at one and four weeks post-challenge as compared to controls. At no point
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during any vaccination protocol were anti-OPS antibodies present in sera of RB51 vaccinates
prior to challenge (Schurig et al 1991). Further studies with pregnant mice infected with B.
abortus strains showed less placental damage and colonization with RB51 than with Strains 19
and 2308 (Tobias et al 1992). Mice vaccinated IP or subcutaneously (SC) with RB51 showed
increased protection against virulent challenge with B. abortus, B. melitensis, and B. ovis
(Jimenez de Bagues et al 1994).
Experiments performed in RB51 vaccinated cattle have shown that the vaccine is cleared
from draining lymph nodes at a rapid rate (Cheville et al 1992). The clinical disease and
pathologic lesions of acute brucellosis are not caused by RB51 (Cheville et al 1996). These
observations were supported with research conducted by Palmer et al in 1997, which determined
that RB51 vaccination in pregnant cattle is non-abortogenic and both humoral and cell-mediated
immune responses are stimulated without infection of fetal or maternal tissues (Palmer et al
1997b). Calves vaccinated SC with RB51 at three to ten months of age were protected from
virulent B. abortus infection at levels comparable to that of Strain 19; therefore, RB51 was
named the official calfhood vaccine for bovine brucellosis by the Animal and Plant Health
Inspection Service, United States Department of Agriculture in 1996 (9 CFR 78; August 12,
1996). In 2004, RB51 received full USDA licensure as a brucellosis vaccine for cattle and bison.
Due to the high prevalence of brucellosis in wild ungulates, RB51 was evaluated as an
oral vaccine candidate. Oral vaccines are used to vaccinate large numbers of a target population.
Mice and cattle were used as models for the oral administration of RB51. Oral vaccination
provided less protective immunity than IP administration against virulent B. abortus challenge in
BALB/c mice (Stevens et al 1996). Cattle were afforded protection from virulent B. abortus
infection by oral vaccination with RB51. Oral vaccinates had a 30% abortion rate and 20% of
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these animals were colonized by virulent B. abortus; however, at no time was RB51 isolated
from vaccinates or their calves (Elzer et al 1998). The oral administration of RB51 has also been
evalutated in dogs and found to be non-pathogenic (Palmer et al 1997a).
RB51 was evaluated as a heterologous vaccine due to the protection it afforded cattle
against virulent B. abortus challenge. Subcutaneous administration of RB51 in swine resulted in
100% colonization of draining lymph nodes. Partial protection against virulent B. suis challenge,
as well as increased litter size and fewer dead piglets compared to controls were found in RB51
vaccinated sows (Hagius et al 1995). Lord et al determined in 1998 that swine were protected
from virulent B. suis challenge by intramuscular (IM) or oral administration of RB51 regardless
of the age of the pigs at vaccination, the vaccine dose, or the number of doses given. Edmonds et
al further evaluated RB51 as a potential oral vaccine for swine in 2001, utilizing a viscous liquid
(Karo syrup) and a scarification mechanism (pecans) which both prolonged adherence and
allowed a route of entry for the vaccine via the oral mucosa. Concentrations of greater than 1 x
1010 CFU of RB51 resulted in 100% colonization of the vaccine strain in draining lymph nodes
when this method was used.
Brucella suis Strain VTRS1. In 1996 Virginia Polytechnic University introduced a
genetically attenuated strain of Brucella suis Strain 2579 (biovar 4) as a potential heterologous
vaccine for brucellosis. This rough mutant, B. suis Strain VTRS1, was produced via allelic
exchange, in which the rfbU gene that encodes for OPS expression was disrupted and replaced
with a kanamycin resistance gene to allow for isolation. There was no reversion to the smooth
phenotype observed during in vivo passage in BALB/c mice, and the vaccine did not induce the
production of anti-OPS antibodies. VTRS1 replicated in mice and offered substantial protection
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against virulent challenge with B. melitensis, B. abortus, and five field strains of B. suis (Winter
et al 1996).
In a small pilot study, VTRS1 was shown to transiently colonize swine and was not
abortogenic when given conjunctively to pregnant sows. Subcutaneous vaccinates challenged
with virulent B. suis at mid-gestation displayed a 0% abortion rate. The challenge strain was not
recovered from vaccinated sow or piglet tissues and at no time were OPS-specific antibodies
detected in the sera of vaccinates prior to challenge (Hagius et al 2001).
Pseudorabies Virus
Pseudorabies virus (PRV), or Aujeszky’s Disease, was first described in 1902. Dr.
Aladar Aujeszky, a Hungarian physician and veterinarian, recovered the virus from a dog, cat,
and ox, and discovered that it was readily transmissible to rabbits and guinea pigs. Pseudorabies
virus is an alphaherpesvirus approximately 180 nanometers in diameter. The virion consists of a
double-stranded DNA genome, an icosahedral capsid made up of 162 capsomeres, and an outer
membrane, or envelope (Gustafson 1981, Hanson 1954).
It is speculated that PRV has been present in the United States since 1813, and it is
currently present in all of Europe, North, Central, and South America, India, Southeast Asia,
Taiwan, North Africa, and New Zealand. This potentially devastating virus has an extremely
broad host range, infecting and causing death in most mammals; however, swine are particularly
resistant to infection and act as a reservoir for PRV. So far there have been no reports of human
infection (Gustafson 1981).
The symptoms of PRV in swine vary from subclinical to death, with cardinal signs
including fever, depression, excessive salivation, and convulsions (Gustafson 1981), and some
strains of PRV will produce a respiratory disease (Lee and Wilson 1979). The mortality rate of
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mature swine with a PRV infection is approximately two percent (Gustafson 1981); however,
mortality is indirectly proportional to age, and therefore PRV is 100% fatal in piglets less than
seven days old (Aiello 1998).
Pseudorabies virus infection of a pregnant sow may lead to infection of fetuses in utero,
and can result in abortion, stillborn, mummified, and/or macerated piglets (Lee and Wilson
1979). If infection occurs during the first 30 days of gestation the embryos are typically
reabsorbed, while from 40 to 60 days gestation, infection results in the death of some or all of the
fetuses and/or premature expulsion. After 80 days gestation, macerated, stillborn, and weak
piglets often result from PRV infection of the sow (Gustafson 1981, Iglesias 1993). Twenty
percent of infected sows will not conceive at the next breeding (Gustafson 1981).
In domestic swine herds PRV is most commonly transmitted by inhalation or ingestion
(Gustafson 1981). The virus can survive in wood, hay, and food for up to 46 days (Lee and
Wilson 1979) and can persist for up to seven hours in air and travel via aerosols for up to two
kilometers in certain weather conditions (Aiello 1998); therefore, swine housed in the same air
space as infected animals may become infected even without direct contact (Iglesias 1993). All
animals are potential lifetime carriers of PRV, and dogs, cats, and feral animals can transmit the
virus between farms prior to death (Aiello 1998, Iglesias 1993).
Feral swine have been shown to primarily transmit PRV to one another through sexual
contact, as with B. suis. Latent infections have been found primarily within the sacral ganglia in
feral swine, as compared to the trigeminal ganglia localization in domestic swine, and feral boars
do not typically transmit the virus to other boars, even when housed together (Romero et al
2001). This evidence, along with the isolation of virus from genital swabs, but not nasal swabs
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of feral swine (Hahn et al 1997), indicates that PRV transmission in feral swine is primarily
venereal.
Pseudorabies virus infection can result in both chronic and latent persistence (Gustafson
1981) with viral dissemination occurring via the central nervous system, the lymphatics, and the
vascular system (Lee and Wilson 1979). The primary sites of viral replication are the nasal
pharyngeal and tonsillar epithelium, depending on the mode of entry of the virus. The virus then
moves to both the regional lymph nodes and the brain and continues replication. Within two to
five days post-infection viral excretion begins, after which live virus can be recovered from nasal
secretions, tonsillar epithelium, vaginal and preputial secretions, milk and urine (Aiello 1998).
There is currently no treatment for PRV and no vaccine available that will prevent
infection, and while both a live attenuated vaccine and an inactivated vaccine are commercially
available, they may interfere with diagnostic tests (Gustafson 1981). As with B. suis, research is
currently underway to develop an efficacious vaccine for PRV that will enable swine herd
owners and veterinarians to differentiate infected animals from vaccinates.
Pseudorabies Virus Glycoproteins
Ten PRV glycoproteins have been identified and characterized to date: gB, gC, gD, gE,
gG, gH, gI, gK, gL, and gM (Mettenleiter 1996). These glycoprotein spikes project from the
virion’s surface and are involved in attachment to host cells, fusion with the cellular membrane,
entry of the nucleocapsid, and mediation of virus spread from infected to uninfected cells
(Mulder et al 1997). The presence of gC, gE, gG, gI, or gM is not essential for infectivity of the
virus; however, the absence of gB, gD, gH, gK, or gL prevents productive replication
(Mettenleiter 1996).
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Glycoprotein D is approximately 50-60 kilodaltons (Mettenleiter 1991), and its
interaction with an unidentified receptor mediates the stable attachment of the virion and
penetration into the host cell; however, it is not required for the subsequent cell-to-cell
transmission of PRV. In cells that express PRV gD the virus can bind but penetration is
inhibited, thus these cells are resistant to infection (Hanssens et al 1995, Mettenleiter 1991,
Mulder et al 1997).
Herpesvirus glycoproteins are the principle antigens that induce host immune responses
(Ishii et al 1988). Several studies have shown that gE, gC, and gD possess epitopes that induce
the production of neutralizing antibodies and are the major targets of immune responses such as
antibody and complement mediated cell lysis, antibody-dependent cell-mediated cytotoxicity,
and cytotoxic T lymphocytes (Ishii et al 1988, Mulder et al 1997). Antibodies against gD are the
most potent for virus neutralization in the absence of complement and inhibit virus penetration,
thereby blocking the first stages of PRV infection (Eliot et al 1988, Mettenleiter 1991,
Mettenleiter 1996).
Glycoprotein D has at least one epitope that induces the synthesis of virus neutralizing
antibodies, making it a potential candidate for a useful subunit vaccine. In mice, gD has been
shown to initiate the formation of virus neutralizing antibodies, and therefore may be as effective
in swine (Ishii et al 1988). When gD was delivered to mice via infection with recombinant
vaccinia virus or as a subunit synthesized in a eukaryotic cell line, PRV-induced mortality was
prevented. In addition, gD that was synthesized in a Chinese Hamster Ovary cell line prevented
lethal PRV infection in swine (Marchioli et al 1987). Vaccination of pigs with plasmid DNA
encoding gD has been shown to stimulate humoral immune responses and protect against
virulent challenge with PRV. The virus was shed from vaccinates for a shorter period of time
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and a decrease in severity of clinical symptoms was observed (Haagmans et al 1999). A
eukaryotic expression vector encoding gD has also been evaluated as a potential PRV vaccine.
When administered to mice via live Escherichia coli, this subunit vaccine elicited cell-mediated
immune responses and partially protected against lethal PRV challenge (Shiau et al 2001).
In diagnostic tests for PRV that are currently available and used for the screening of
swine herds, the presence of antibodies to proteins other than gD interfere with the
differentiation between infected swine and vaccinates (Marchioli et al 1987). The use of gD as a
vaccine for PRV in swine would eliminate this uncertainty. This advantage, coupled with the
fact that gD is the target of neutralizing antibodies that can protect mice and swine from PRV
disease, make gD the perfect candidate for an effective subunit vaccine.
Feral Swine
Feral swine (Sus scrofa) are wild-living descendents of domestic swine that interbred
years ago with the Eurasian wild boar, and were introduced into the United States by European
immigrants during colonial times. The population of free-living feral swine in the United States
is now estimated at over two million (Conger et al 1999) spread out over at least 32 states
(Romero 2001).
The overall incidence of B. suis and PRV in feral swine is estimated at 10-25% and 60%,
respectively (Conger et al 1999, Hahn et al 1997). The mixing of feral and domestic pigs, and
the feeding of offal and aborted fetuses to domestic pigs allows for the transmission and
perpetuation of these diseases (Hahn et al 1997). Farmers that introduce feral swine into their
domestic herds are 2.8 times more likely to also introduce B. suis, and the risk of the herd
contracting PRV also increases by 8.9 times. Due to its potential airborne transmission, simply
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having feral swine in the same neighborhood as a domestic herd increases the chances of
contracting PRV by 3.1 times (Dees 1999).
Since the reservoirs of B. suis and PRV are primarily feral swine, this population should
be the target of vaccination programs, and considering the nature of the recipients, oral
administration would provide the easiest mode of vaccination. The most efficacious vaccine for
B. suis, VTRS1, combined with the most immunogenic subunit of PRV, gD, could quite possibly
offer a multivalent vaccine for both diseases that could be administered orally to the feral swine
population.
The goal of this project is to evaluate the use of the rough attenuated strains RB51 and
VTRS1 as oral vaccines for swine brucellosis, and to determine whether the addition of a
plasmid encoding for the PRV gD stimulates immune responses to rough Brucella antigens and
gD while transiently colonizing lymph node tissues. Future research evaluating the efficacy of
these multivalent vaccines against pseudorabies in swine is necessary; however, it is hoped that
these vaccines may ultimately assist in brucellosis and pseudorabies eradication programs by
targeting the feral swine population.
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CHAPTER 3: MATERIALS AND METHODS
Brucella Strains
B. abortus Strain RB51 and B. suis Strain VTRS1 were used as vaccine strains, and B.
suis biovar 1 Strain 1330 was used as the challenge strain. Additionally, B. abortus Strain 2308
cell lysates were used for immunological assays. Stocks of RB51 B. suis 1330, and B. abortus
2308 were plated onto Schaedler blood agar (SBA) plates, and VTRS1 was plated onto SBA
plates supplemented with 45 ug/ml kanamycin. Plates were incubated at 37oC, 5% CO2, for 4872 hours. Bacterial lawns were harvested with Brucella broth and turbid metrically aliquoted
into 1.5 ml cryovials containing 1 x 109, 1 x 1010, or 1 x 1011 CFU/ml. These infectious doses
were snap frozen in liquid nitrogen and stored at –80oC. Serial dilutions of each strain were
plated after preparation and prior to each vaccination or challenge to determine viable counts of
bacteria.
Animals and Breeding
Pigs were purchased from the Louisiana State University AgCenter Swine Unit, Baton
Rouge, LA, or the Wade Correctional Center, Homer, LA, both of which are certified
brucellosis-free facilities. The swine were housed at the Ben Hur Large Animal Isolation
Facility, a USDA/APHIS/VS/CDC approved facility, provided with water ad lib, and fed ground
corn. Prior to vaccination all swine were deemed Brucella antibody-negative by the Brucella
Card test and Western immunoblot analysis. Prior to breeding gilts were administered 7 ml of
Regu-Mate ® (altrenogest) Solution 0.22% (2.2 mg/ml) (DPT Laboratories, San Antonio, TX)
orally for 14 days in order to synchronize their estrus cycles. Three to six days later gilts were
individually bred with a Brucella-negative boar. Pregnancy was confirmed via ultrasound. All
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animals were treated humanely in accordance with LSU AgCenter Animal Care and Use
Committee guidelines.
Genetic Manipulation of Vaccine Strains
The PRV gD antigen was incorporated into RB51 and VTRS1 via the plasmid pBBgroE
ssLgD-CMR, obtained from Purdue University. One hundred ul of 1 x 109 CFU/ml RB51 or
VTRS1 was streaked onto SBA plates, grown for 2-3 days at 37oC, 5% CO2, and harvested with
sterile Brucella broth (Difco Laboratories, Detroit, MI). The harvested bacteria were used to
inoculate 25 ml of sterile Brucella broth which was incubated in a 37oC shaking water bath for
24 hours. The culture was centrifuged for 5 minutes at 15,000 rpm, the supernatant was
discarded, and the pellet was re-suspended in 1 ml cold dH2O. The pellet was then washed three
times with 1 ml cold dH2O, and the final pellet was re-suspended in 100 ul cold dH2O. Thirtythree ul of cold suspension and 5 ul of cold plasmid solution were combined into an ice cold 2
mm, 400 ul Eppendorf Electroporation Cuvette (Brinkmann Instruments, Inc., Westbury, NY).
This solution was electroporated at 2.5 kV using an Eppendorf Electroporator 2510 (Brinkmann
Instruments, Inc., Westbury, NY). Five hundred ul of cold SOC-B (6% trypticase soy broth, 10
mM NaCL, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, 20 mM glucose) (Lai et al 1990)
recovery media was added to the solution, and the final culture was incubated in a 37oC shaking
water bath overnight. One hundred ul of the recovered culture was spread on SBA plates
supplemented with 30 ug/ml chloramphenicol. Plates were incubated at 37oC, 5% CO2 and
monitored daily. Resultant colonies were patched onto SBA plates supplemented with 30 ug/ml
chloramphenicol and incubated at 37oC, 5% CO2, overnight, after which they were inoculated
into 5 ml Brucella broth supplemented with 30 ug/ml chloramphenicol and incubated overnight
in a 37oC shaking water bath.
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Plasmid minipreps were performed on colonies to confirm the presence of pBBgroE
ssLgD using the Qiagen Buffer System (Qiagen, Inc., Valencia, CA). After centrifuging 1.5 ml
of RB51+gD or VTRS1+gD culture at 9000 rpm for 5 minutes and discarding the supernatant,
the pelleted cells were resuspended in 300 ul of 100% chloroform and 300 ul P1 buffer (50 mM
Tris base, 10 mM EDTA, 10 ug/ml RNaseA). This suspension was centrifuged at 15,000 rpm
for 5 minutes, after which the aqueous and cell layers were transferred to a clean tube, combined
with 300 ul of P2 buffer (200 mM NaOH, 1% SDS), and mixed by gently inverting the tube.
Three hundred ul of chilled P3 buffer (3.0 M CH3CO2K) was then added and the suspension was
again gently mixed by inverting the tube. After centrifuging the solution at 14,000 rpm for 10
minutes, the supernatant was placed into a clean tube. Plasmid DNA was precipitated with 630
ul of isopropanol and the suspension was centrifuged at 14,000 rpm for 15 minutes. The
supernatant was removed and the pellet was allowed to dry. The pellet was re-suspended in 25
ul 1X TE (1 mM Tris, 0.1 mM EDTA) and incubated at 4oC for 1 hour. The presence of plasmid
DNA was verified via agarose gel electrophoresis by running 10 ul of plasmid DNA on a 0.7%
agarose gel at 90 V for 1 hour. After staining with ethidium bromide, the presence of a band at
7.2 Kb confirmed the presence of pBBgroE ssLgD-CMR. Once the plasmids were confirmed,
25% glycerol stocks and 1 x 109 and 1 x 1011 CFU/ml infectious doses were made of RB51+gD
and VTRS1+gD.
Vaccine Routes
Pigs were vaccinated either orally or SC. For SC vaccination, 1 x 1010 CFU of each
vaccine was inoculated into the right cervical area using a 3 ml syringe with a 20 gauge, 1 inch
needle. Oral vaccines were prepared by adding a 1 x 1011 CFU/ml infectious dose of each strain
to 9 ml sterile injectable saline and 10 ml Karo syrup, and 3 ml of the resultant mixture was
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poured over a 2:1 mixture of pecan shells to cracked corn. This was fed to each pig individually
to ensure that each animal received greater than 1 x 1010 CFU of the vaccine. Controls received 3
ml of a 1:1 mixture of Karo syrup to sterile injectable saline. To facilitate oral mucosa exposure,
Karo syrup, which prolongs the adherence of the brucellae, and pecan shells were used to scarify
the mucosa (Edmonds 2001).
Serum Collection
Pigs were bled from the brachiocephalic vein using an 18 gauge, 1.5-inch needle and 20
ml syringe (Lawhorn 1988). Sera were separated via centrifugation and stored at –20oC until
tested.
Serological Testing
All sera were tested by the Card test and Western immunoblot analysis as previously
described (Edmonds et al 2001). Briefly, for Western immunoblots, glycerol stocks of Brucella
strains were plated onto SBA plates and grown for 2-3 days at 37oC, 5% CO2. Cells were
harvested with Phosphate Buffered Saline (PBS), sonicated for 8 minutes, and boiled for 10
minutes. The resultant cell lysates were diluted 1:1 with Laemmli sample buffer (BioRad
Laboratories, Hercules, CA) and boiled an additional 10 minutes. VTRS1+gD and RB51+gD
were plated onto SBA plates supplemented with 30 ug/ml chloramphenicol and incubated at
37oC, 5% CO2, for 3-4 days. Cells were harvested and used to inoculate 5 ml of Brucella broth
supplemented with 30 ug/ml chloramphenicol and incubated in a 37oC shaking water bath
overnight. The bacteria were then heat shocked in a 42oC shaking water bath for 30 minutes to
increase plasmid copy number, then centrifuged for 5 minutes at 15,000 rpm. The supernatant
was discarded and cells were re-suspended in 2 ml dH2O. Suspensions were sonicated and
antigens prepared as described above. Various concentrations of cell lysates were separated by
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polyacrylamide gel electrophoresis (PAGE) using 12% Tris-HCl BioRad Ready Gels (BioRad
Laboratories, Hercules, CA) at 150 V for 45 minutes. Proteins were transferred onto
nitrocellulose paper at 100 V for 1 hour. The nitrocellulose was then blocked with 5% non-fat
milk, washed five times with Tris-Buffered Saline (TBS)-Tween and once with TBS (0.5 M
NaCl, 20 mM Tris). Blots were individually incubated overnight at room temperature on a
shaker with a 1:40 dilution of serum to be tested. After another washing cycle, blots were next
incubated for 45 minutes at room temperature on a shaker with a 1:800 dilution of anti-pig IgG
peroxidase conjugate (Sigma-Aldrich, St. Louis, MO). Blots were developed after a third
washing cycle with 4-chloro-1-naphthol (Sigma-Aldrich Co., St. Louis, MO) and allowed to dry.
Necropsy
Pregnancies were monitored until delivery and the numbers of live, stillborn, or aborted
piglets were recorded. Piglets were euthanized by CO2 asphyxiation if necessary, and samples of
lung tissue and stomach fluid were taken from all piglets. Upon completion of the study, sows
were euthanized at a USDA-inspected slaughterhouse by captive-bolt and exsanguination. Blood
samples were collected and serological analyses were performed as described above. The
following tissues were collected: parotid, prescapular, internal iliac, and supramammary lymph
nodes; mammary gland; liver; spleen; and uterine swab.
Bacteriological Analysis
Tissue samples were weighed and homogenized in 20 ml PBS. One hundred ul of each
sample was plated onto SBA plates supplemented with Brucella Selective Supplement (Oxoid
Ltd., Basingstoke, Hampshire, England). Plates were incubated at 37oC, 5% CO2, for 14 days,
after which colonies were counted and CFU/gram of tissue was calculated. Uterine swabs were
streaked onto SBA plates supplemented with Brucella Selective Supplement and incubated at
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37oC, 5% CO2, for 14 days and recorded as positive or negative based on the presence or absence
of colonies. RB51+gD or VTRS1+gD colonies were patched onto SBA plates supplemented
with 30 ug/ml chloramphenicol or 45 ug/ml kanamycin and 30 ug/ml chloramphenicol,
respectfully, to ensure that the plasmid was still present.
Experimental Design
Serologic Responses. Twelve sexually immature pigs (2-3 months old) were randomly
placed into two groups: six RB51 vaccinates and six VTRS1 vaccinates. All swine were orally
vaccinated with greater than 1 x 1010 CFU of the vaccine each day for three consecutive days at
0, 4, 6, and 8 weeks. Serum was obtained prior to vaccination and ten days following each
vaccine exposure, and analyzed as described above.
Colonization. Fifty-two sexually immature pigs (2-3 months old) were randomly
assigned into vaccination groups as follows: nine SC vaccinated with RB51+gD, nine SC
vaccinated with VTRS1+gD, seven orally vaccinated with RB51+gD, seven orally vaccinated
with VTRS1+gD, ten SC vaccinated with VTRS1 and ten orally vaccinated with VTRS1.
Subcutaneous vaccinates received 1 x 1010 CFU once, while oral vaccinates received greater than
1 x 1010 CFU each day for three consecutive days. Two to four pigs from each group were
euthanized at either day 10, 24, or 31, post vaccination. Samples of the parotid, prescapular, and
internal iliac lymph nodes, liver, and spleen were collected for bacteriological analysis. Serum
was obtained prior to vaccination and at necropsy, and analyzed as described above.
Pathogenesis. Seventeen pregnant sows were obtained and randomly assigned into three
groups. At mid-gestation two groups of five sows were challenged with 1 x 109 CFU of either
RB51+gD or VTRS1+gD in 100 ul of PBS by administering half of the inoculum into the
conjunctival sac of each eye. Since the vaccines are rough and thought to be semi-attenuated,

23

these groups received two logs greater CFUs as compared to the smooth virulent control strain.
As positive controls seven sows were challenged with 1 x 107 CFU of the virulent strain B. suis
1330 conjunctivally. At parturition lung tissue and stomach fluid of live piglets that were
euthanized with CO2, aborted, and still-born piglets were collected then cultured. One month
post-parturition all sows were euthanized and the following tissues were collected for
bacteriological analysis: parotid, prescapular, internal iliac, and supramammary lymph nodes;
mammary gland; liver; spleen; and uterine swab. Serum was obtained prior to challenge and at
necropsy, and processed as described above.
Vaccine Efficacy. Forty-eight eight-month-old gilts were randomly assigned into
groups: ten VTRS1 oral vaccinates, six RB51 oral vaccinates, ten VTRS1+gD SC vaccinates, ten
VTRS1+gD oral vaccinates, five RB51+gD oral vaccinates, and seven saline controls. Swine
were vaccinated orally with greater than 1 x 1010 CFU each day for three days or once
subcutaneously with 1 x 1010 CFU. Four weeks post-vaccination, all orally vaccinated swine
were boosted at two-week intervals in the same manner for a total of four exposures to the
vaccines. Subcutaneous vaccinates were boosted once four weeks post-vaccination for a total of
two exposures to the vaccines. Four weeks following the final boost the gilts were naturally
serviced. At mid-gestation all swine were challenged with 1 x 107 CFU of the virulent strain B.
suis 1330 in 100 ul of PBS by administering half of the inoculum into the conjunctival sac of
each eye. At parturition lung tissue and stomach fluid of live piglets that were CO2 euthanized,
aborted, and still-born piglets were collected for culture. One month post-parturition all sows
were euthanized and samples of the following tissues were collected for bacteriological analysis:
parotid, prescapular, internal iliac, and supramammary lymph nodes; mammary gland; liver;
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spleen; and uterine swab. Serum was obtained prior to vaccination, ten days following the final
boost, prior to challenge, and at necropsy, and was tested as described above.
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CHAPTER 4: RESULTS
Transformation of VTRS1 and RB51 with pBBgroE ssLgD
The parent strains VTRS1 and RB51 were electroporated with pBBgroE ssLgD, which
encodes for the PRV gD protein via the cloning vector pBBR1MCS. This vector has been
shown to be stably maintained extrachromasomally at a low copy number in both B. abortus and
B. suis (Elzer et al 1995, Kovach et al 1994). Following transformation, plasmid minipreps were
performed on colonies displaying chloramphenicol resistance, and the presence of plasmid DNA
was visualized via agarose gel electrophoresis. Positive colonies contained plasmid DNA that
migrated at approximately 7.2 kilobases (Kb) (Figure 1). In order to evaluate the growth of the
resultant vaccines, VTRS1+gD and RB51+gD, 1 x 109 CFU/ml infectious doses of these strains
as well as VTRS1 and RB51 were serially diluted and plated onto either SAB, SAB
supplemented with Brucella Selective Supplement, or SAB supplemented with 30 ug/ml
chloramphenicol. While the parent strain colonies grew after three to four days of incubation,
VTRS1+gD and RB51+gD colonies required an additional 48 hours for growth. Plate counts of
the transformed strains did not differ significantly from those of the parent strains (data not
shown).
Serological Responses in Swine Orally Vaccinated with VTRS1 and RB51
Sexually immature pigs in each group were orally vaccinated with either RB51 or
VTRS1 at weeks 0, 2, 4, and 6, and serological responses to rough Brucella antigens were
determined via Western immunoblot analysis using RB51 and VTRS1 cell lysates ten days
following each vaccination.
Fifty percent of RB51 vaccinates and 16.7% of VTRS1 vaccinates had a positive
serological response to rough Brucella antigens after the first oral exposure. As expected, the
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2

7.2 Kb

Figure 1 – Agarose gel electrophoresis of pDNA recovered from transformed vaccine
strains. Lane 1: VTRS1+gD pDNA; Lane 2: RB51+gD pDNA.
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number of seropositive pigs increased with each exposure to the vaccine, with 100% of RB51
vaccinates and 83.3% of VTRS1 vaccinates seropositive for rough Brucella antigens after four
exposures to the vaccines (Table 1). At no time during the study were any of the vaccinates
seropositive for the OPS antigens of smooth Brucella, as evidenced by the Card test and Western
immunoblot analysis using B. abortus Strain 2308 and B. suis Strain 1330 cell lysates.
Colonization of VTRS1
Sexually immature pigs were vaccinated either orally or SC with VTRS1 and necropsied
at day 10, 24, or 31. Lymph nodes were collected for bacteriological analysis and serum was
tested for antibodies to rough Brucella antigens via Western immunoblot analysis using VTRS1
cell lysates.
VTRS1 was isolated from the parotid, prescapular, or internal iliac lymph nodes, or the
liver or spleen of eight of the 20 vaccinates (40%). Subcutaneous vaccinates necropsied at day
10 or 24 had the greatest number of colonized tissues, 20% and 15%, respectively. Ninety
percent of SC vaccinates and 80% of oral vaccinates were seropositive for rough Brucella
antigens at necropsy (Table 2), confirming immune response stimulation and therefore vaccine
exposure. At no point during the study were any vaccinates seropositive for the OPS antigens of
smooth Brucella, as evidenced by the Card test and Western immunoblot analysis using B. suis
Strain 1330 cell lysates.
Colonization of VTRS1+gD and RB51+gD
Sexually immature pigs were vaccinated SC or orally with either VTRS1+gD or
RB51+gD. On day 10, 24, or 31 post-vaccination, pigs were necropsied and lymph nodes
collected for bacteriological analysis. Serum was also collected pre-vaccination and at necropsy
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Table 1 – Serological responses of pigs orally vaccinated with RB51 or VTRS1
Vaccine
strain

Dose*

No. of
pigs

RB51

1 x 1010 (x3)

6

VTRS1

1 x 1010 (x3)

6

No. of serologic responders§
Exposure Exposure Exposure Exposure
1
2
3
4
3
5
6
6
1

2

*

5

5

CFU/pig; Pigs were given the oral vaccine three consecutive days for each exposure.
Western immunoblot using strains RB51 and VTRS1 cell lysates performed ten days post-exposure.

§
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Table 2 – Colonization and serological responses of pigs vaccinated subcutaneously or
orally with VTRS1
Route*

Dose**

No. of
pigs

Necropsy
(dpv)†

SC

1 x 1010

3

SC

1 x 1010

SC
Oral
Oral
Oral

10

No. of
serologic
responders‡
2

No.
culture
positive§
2

4

24

4

2

1 x 1010

3

31

3

1

1 x 1010
(x3)
1 x 1010
(x3)
1 x 1010
(x3)

3

10

2

1

4

24

3

1

3

31

3

1

*

Culture
positive
tissuesa
3/15
(38-125)
3/20
(59-182)
1/15
(74)
1/15
(333)
2/20
(100-8333)
1/15
(258)

SC vaccinates were exposed to VTRS1 once, while oral vaccinates were exposed three consecutive days.
CFU/pig.
†
Days post-vaccination.
‡
Western immunoblot using Strain VTRS1 cell lysate.
§
Tissues collected: parotid, prescapular, and internal iliac lymph nodes, liver, and spleen.
a
Culture positive tissues/ total number of tissues collected per group (range of CFU per gram of tissue).
**
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and tested by Western immunoblot analysis for the presence of antibodies to rough Brucella
antigens and PRV gD.
The vaccine strain was recovered from two of the 16 sexually immature pigs exposed
either SC or orally to RB51+gD (12.5 %) (Table 3). VTRS1+gD was cultured from eight of the
16 vaccinated pigs (50%) (Table 4). Both vaccine strains were isolated from the draining lymph
nodes and secondary lymphatic tissue (liver, spleen, and internal iliac lymph node) and colonies
were transferred to SBA plates supplemented with chloramphenicol to ensure that the plasmid
was not lost in the host. All vaccinates, including those colonized with the vaccine strains, were
seronegative for smooth Brucella at all time points, as evidenced by the Card test and Western
immunoblot analysis using B. abortus Strain 2308 and B. suis Strain 1330 cell lysates.
Serological responses to rough Brucella antigens were observed in 88.9% of SC and
71.4% of oral RB51+gD vaccinates (Table 3), while the VTRS1+gD vaccine provided 77.8%
and 100% positive rough Brucella serology when administered SC and orally, respectively
(Table 4). A positive serological determination, as evidenced by Western immunoblot analysis
using RB51 and VTRS1 cell lysates, indicates that the rough Brucella antigens were seen by the
vaccinates’ immune systems.
A serological response to PRV gD was also measured by Western immunoblot analysis
using purified PRV gD and RB51+gD cell lysates. Three of the nine (33.3%) SC RB51+gD
vaccinates were positive for gD serology, while six of the nine (66.7%) SC VTRS1+gD
vaccinates were positive. Only one pig from each oral vaccine group was positive for PRV gD
antibodies (Tables 3 and 4).
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Table 3 – Colonization and serological responses of pigs vaccinated subcutaneously or
orally with RB51+gD
Route*

Dose**

No. of
pigs

Necropsy
(dpv)†

No. of
serologic
‡
responders

No.
culture
positivea

Culture
positive
tissuesb

SC

1 x 1010

No. of
serologic
responders
to gD§

3

10

2

0

1

SC

1 x 1010

3

24

3

2

0

1/15
(1850)
0/15

SC

1 x 1010

3

31

3

1

0

0/15

Oral

1 x 1010
(x3)
1 x 1010
(x3)
1 x 1010
(x3)

2

10

1

1

0

0/10

3

24

2

0

0

0/14

2

31

2

0

1

3/10
(45-462)

Oral
Oral
*

SC vaccinates were exposed to RB51+gD once, while oral vaccinates were exposed three consecutive days.
CFU/pig.
†
Days post-vaccination.
‡
Western immunoblot using Strain RB51 cell lysate.
§
Western immunoblot using purified gD and Strain RB51+gD cell lysate.
a
Tissues collected: parotid, prescapular, and internal iliac lymph nodes, liver, and spleen.
b
Culture positive tissues/ total number of tissues collected per group (range of CFU per gram of tissue).
**
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Table 4 – Colonization and serological responses of pigs vaccinated subcutaneously or
orally with VTRS1+gD
Route*

Dose**

No. of
pigs

Necropsy
(dpv)†

No. of
serologic
‡
responders

No.
culture
positivea

Culture
positive
tissuesb

SC

1 x 1010

No. of
serologic
responders
to gD§

3

10

2

2

0

0/15

SC

1 x 1010

3

24

2

2

1

SC

1 x 1010

3

31

3

2

3

Oral

1 x 1010
(x3)
1 x 1010
(x3)
1 x 1010
(x3)

2

10

2

1

0

2/15
(54-727)
3/14
(16-71)
0/10

3

24

3

0

2

2

31

2

0

1

Oral
Oral
*

2/15
(63-167)
2/15
(27-43)

SC vaccinates were exposed to VTRS1+gD once, while oral vaccinates were exposed three consecutive days.
CFU/pig.
†
Days post-vaccination.
‡
Western immunoblot using Strain VTRS1 cell lysate.
§
Western immunoblot using purified gD and Strain VTRS1+gD cell lysate.
a
Tissues collected: parotid, prescapular, and internal iliac lymph nodes, liver, and spleen.
b
Culture positive tissues/ total number of tissues collected per group (range of CFU per gram of tissue).
**
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VTRS1+gD and RB51+gD Pathogenesis in Pregnant Swine
Pregnant sows were challenged conjunctively with 1x109 CFU of VTRS1+gD or
RB51+gD, or 1x107 CFU of virulent B. suis at mid-gestation. Two logs greater CFU of the
vaccines were used due to their rough morphology and attenuated nature. At parturition the
numbers of live, stillborn, and aborted piglets were recorded, and samples of lung tissue and
stomach fluid collected for bacteriological analysis. Four weeks post-parturition the sows were
necropsied and bacteriological analysis of lymph nodes was performed. Serum was collected
prior to challenge and at necropsy and tested via the Card test and Western immunoblot analysis.
The average litter size of sows challenged with VTRS1+gD was 11.4 piglets, 86% of
which were born live, and RB51+gD challenged sows yielded an average litter size of 11.5
piglets and a live birth rate of 87%. The vaccine strains were not recovered from any of the
piglet or sow tissues cultured thus far, while all of the control sows challenged with virulent B.
suis and their litters were culture positive for the challenge strain (Table 5). Two RB51+gD
challenged sows have not yet farrowed, and four other sows have not yet been necropsied. This
study is ongoing and tissues from the remaining pigs will be evaluated once collected.
Efficacy of Oral VTRS1 and RB51 Vaccination
Gilts were vaccinated orally with VTRS1, RB51, or saline for three consecutive days at
weeks 0, 4, 6, and 8, and then bred with a Brucella negative boar four weeks following the final
boost. At mid-gestation all gilts were challenged conjunctively with 1 x 107 CFU of virulent B.
suis, and pregnancies were monitored until delivery. At parturition the numbers of live, stillborn,
or aborted piglets were recorded and samples of lung tissue and stomach fluid were collected for
bacteriological analysis. Sows were necropsied four weeks post-parturition and bacteriological
analysis of lymph nodes was performed. Serum was analyzed via the Card test and Western
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Table 5 – Delivery status and culture results for sows challenged at mid-gestation with
VTRS1+gD, RB51+gD, or virulent B. suis
Group

No.
of
pigs

Challenge
Dose*

No. of
live
piglets

No. of
dead
piglets

No. of sows
culture
positive§

Tissues
culture
positivea

VTRS1+gD

5

1 x 109

No. of
litters
culture
positive†

49

8

0/5

0/4

0/21

RB51+gD

5

1 x 109

40

6

0/3

0/2

0/14

B. suis

7

1 x 107

39

5

4/4‡

6/6

30/42
(30-11,550)

*

CFU/pig; due to the rough morphology and attenuated nature of the vaccine strains, these groups received two logs
greater CFU than pigs challenged with smooth virulent B. suis.
†
Tissues collected from piglets: lung tissue and stomach fluid.
‡
One saline control sow reabsorbed her fetuses shortly after challenge and another farrowed too close to the
challenge date; therefore, these two litters were excluded from the study.
§
Tissues collected from sows: parotid, prescapular, supramammary, and internal iliac lymph nodes, mammary gland,
liver, spleen, and uterine swab.
a
Culture positive tissues/ total number of tissues collected per group (range of CFU per gram of tissue).
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immunoblot analysis prior to vaccination, ten days following the final boost, prior to challenge,
and at necropsy. Three gilts, two RB51 vaccinates and one VTRS1 vaccinate, failed to conceive
and were therefore excluded from the study.
Eight of the nine (89%) VTRS1 vaccinates were seropositive for rough Brucella antigens
prior to virulent B. suis challenge as evidenced by Western immunoblot analysis using RB51 and
VTRS1 cell lysates, while only three of the four (75%) RB51 vaccinates were positive. No
control sows were seropositive for rough Brucella antigens (Table 6), and at no point prior to
challenge were antibodies specific for the OPS antigens of smooth Brucella detected in any of
the gilts, as determined via the Card test and Western immunoblot analysis using B. abortus
2308 and B. suis 1330 cell lysates.
The average litter size of sows vaccinated with VTRS1 was nine piglets, 93.8% of which
were born live. The challenge strain was recovered from either lung tissue or stomach fluid of
three of the nine (33%) litters and six of the nine (67%) sows were culture positive for virulent B.
suis four weeks post-parturition (Table 6). The challenge strain was present in the
primary and secondary lymph nodes and the spleen of the majority of culture-positive sows, but
was also recovered from the mammary gland and liver of three sows and one sow’s uterine swab
(Table 7).
RB51 vaccinates yielded an average litter size of eight piglets. One sow aborted her litter
of 11 piglets at 14 weeks gestation, six weeks after challenge; however, she was in poor health
due to an abscess on her right hind leg and the challenge strain was not recovered from the
aborted fetuses. The remaining piglets born to RB51-vaccinated sows (64%) were born live.
The challenge strain was not cultured from the lung tissue or stomach fluid of any of the litters;
however, 75% of the sows were culture positive for virulent B. suis four weeks post-parturition
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Table 6 – Delivery status and culture results for swine vaccinated orally with VTRS1,
RB51, or saline and challenged at mid-gestation with 1 x 107 CFU of virulent B. suis
Group

No. of
pigs

No. of
serologic
responders*

No. of live
piglets

No. of dead
piglets

No. of litters
culture positive§

No. of sows
culture
positivea

VTRS1

9

8/9

76

5

3/9

6/9

RB51

4

3/4

21

11†

0/4

3/4

Saline

7

0/7

39

5

4/4‡

6/6

*

Western immunoblot using strains VTRS1 and RB51 cell lysates performed prior to challenge, after a total of four
oral exposures to the vaccine or saline.
†
One RB51 vaccinate aborted at approximately 14 weeks gestation, 6 weeks after challenge; however, she was in
poor health due to an abscess on her leg and no piglets were culture positive for the challenge strain.
§
Tissues collected from piglets: lung tissue and stomach fluid.
‡
One saline control sow reabsorbed her fetuses shortly after challenge and another farrowed too close to the
challenge date; therefore, these two litters were excluded from the study.
a
Tissues collected from sows: parotid, prescapular, supramammary, and internal iliac lymph nodes, mammary gland,
liver, spleen, and uterine swab.
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Table 7 – Bacteriological analysis of tissues collected from sows orally vaccinated with
VTRS1, RB51, or saline and challenged at mid-gestation with 1 x 107 CFU of virulent B.
suis

VTRS1

Vaccine Strains*
RB51

Saline

Stomach Fluid

2/9† (22%)
0.5 (+1.04) ‡

0/4 (0%)
0§

4/4 (100%)
3.0 (+1.30)

Lung

1/9 (11%)
0.3 (+0.80)

0/4 (0%)
0§

3/4 (75%)
2.6 (+1.94)

Parotid LNa

5/9 (56%)
1.3 (+1.28)

3/4 (75%)
2.4 (+1.70)

5/6 (83%)
2.3 (+1.36)

Prescapular LN

4/9 (44%)
0.9 (+1.14)

3/4 (75%)
2.4 (+1.68)

5/6 (83%)
2.0 (+0.98)

Supramammary LN

4/9 (44%)
1.1 (+1.51)

3/4 (75%)
2.2 (+1.51)

5/6 (83%)
2.2 (+1.23)

Mammary Gland

3/9 (33%)
0.9 (+1.39)

2/4 (50%)
1.6 (+1.98)

3/6 (50%)
1.1 (+1.18)

Liver

3/9 (33%)
0.7 (+1.09)

2/4 (50%)
1.8 (+2.07)

3/6 (50%)
1.0 (+1.07)

Spleen

4/9 (44%)
1.1 (+1.47)

3/4 (75%)
1.9 (+1.42)

6/6 (100%)
2.5 (+0.59)

Internal Iliac LN

4/9 (44%)
1.2 (+1.47)

2/4 (50%)
1.6 (+1.93)

3/6 (50%)
1.3 (+1.40)

Uterine Swab

1/9 (11%)

0/4 (0%)

2/6 (33%)

Card Test

8/9 (89%)

2/4 (50%)

4/6 (67%)

Litter Colonization

Sow Colonization

*

Four oral exposures to 1 x 1010 CFU of VTRS1 or RB51, or saline; pigs were given the vaccine three consecutive
days for each exposure.
†
Number colonized/ number in treatment group.
‡
Mean log CFU/gram of tissue.
§
Limit of detection = 13 CFU/gram.
a
LN = lymph node
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(Table 6). The challenge strain was isolated from both primary and secondary lymph nodes, the
liver and spleen, and the mammary gland of infected sows. Uterine swabs were all culture
negative for virulent B. suis (Table 7).
Eighty-nine percent of the piglets born to saline control sows were live, with an average
litter size of 7.3 piglets (Table 6). One sow reabsorbed her piglets shortly after challenge and
another farrowed too close to the challenge date for her piglets to become infected. Both of these
litters were excluded from the study; however, the sows were evaluated for colonization and
serology post-parturition. All litters and sows were culture positive for the challenge strain
(Table 6), with the lung tissue and stomach fluid of the piglets and the sows’ primary and
secondary lymph nodes and spleens containing the highest numbers of CFU per gram of tissue
(Table 7).
Overall the litters of sows that were vaccinated orally with either VTRS1 or RB51 were
significantly protected against infection with virulent B. suis (approximately three logs of
protection as compared to saline controls). Oral vaccination with RB51 did not protect the
sows; however, sows vaccinated orally with VTRS1 were afforded approximately one log of
protection against virulent challenge as compare to saline controls (Table 7).
Evaluation of Oral and Subcutaneous Vaccination with VTRS1+gD and RB51+gD
Gilts were SC vaccinated with VTRS1+gD at weeks 0 and 4, or orally vaccinated with
VTRS1+gD, RB51+gD, or saline for three consecutive days at weeks 0, 4, 6, and 8. These gilts
are currently being bred with a Brucella negative boar and will be challenged conjunctively at
mid-gestation with 1 x 107 CFU of virulent B. suis. At parturition the number of live, stillborn,
and aborted piglets will be recorded and lung tissue and stomach fluid will be collected for
bacteriological analysis. Sows will also be necropsied four weeks post-parturition and
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bacteriological analysis of lymph nodes will also be performed. Serum was collected prior to
vaccination and ten days following the final boost and analyzed via the Card test and Western
immunoblot analysis using VTRS1, RB51, and RB51+gD cell lysates, and purified PRV gD. At
necropsy serum will also be collected and tested. The serological analysis of pre-vaccination and
post-vaccination sera will be discussed.
Subcutaneous vaccination with strain VTRS1+gD afforded the highest serologic
response, with all vaccinates seropositive for rough Brucella antigens and 77.8% seropositive for
PRV gD. Oral administration of VTRS1+ gD and RB51+ gD resulted in 70% and 60% of
vaccinates mounting an immune response to rough Brucella antigens, respectively. Serologic
responses to PRV gD in oral vaccinates were somewhat lower, with 20% of VTRS1+ gD
vaccinates and 60% of RB51+ gD vaccinates positive for gD-specific antibodies (Table 8). At
no point prior to challenge with virulent B. suis were any pigs shown to be positive for smooth
Brucella anti-OPS antibodies, as determined by the Card test and Western immunoblot analysis
using B. abortus Strain 2308 and B. suis Strain 1330 cell lysates.
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Table 8 – Serological responses of pigs vaccinated with VTRS1+gD or RB51+gD
Vaccine strain

Route*

Dose**

No. of
exposures

No. of
pigs

No. of serologic
responders to
gD§

VTRS1+ gD

SC

1 x 1010

No. of
serologic
responders‡

3

9

9

7

VTRS1+ gD

Oral

5

10

7

2

RB51+ gD

Oral

1 x 1010
(x3)
1 x 1010
(x3)

5

5

3

3

*

Each SC exposure consisted of one dose, while oral vaccinates received three doses per exposure on consecutive
days.
**
CFU/pig.
‡
Western immunoblot using Strain RB51 and VTRS1 cell lysates.
§
Western immunoblot using purified gD and Strain RB51+gD cell lysate.
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CHAPTER 5: DISCUSSION
Oral vaccination for brucellosis utilizing the rough attenuated vaccine RB51 has been
evaluated in several animal species. BALB/c mice and cattle were afforded partial protection
against virulent B. abortus challenge when orally vaccinated with RB51; however, protection
was not as high as that provided by IP or SC RB51 administration (Elzer et al 1998, Stevens et al
1996). Oral RB51 vaccination of dogs was found to be non-pathogenic (Palmer et al 1997), and
Lord et al found no differences in the protection provided by oral or IM vaccination of swine to
virulent B. suis challenge (Lord et al 1998). Vaccination with RB51 has also been evaluated in
bison and elk (Cook et al 2002, Olsen et al 2003).
In the current study, oral administration of VTRS1 and RB51 was shown to stimulate the
production of antibodies specific to rough Brucella antigens in the majority of pigs vaccinated.
As expected, the number of serological responders increased with the number of oral exposures
to the vaccines, with 100% of RB51 vaccinates sero-positive for rough Brucella antigens after
the third exposure. The serological response to orally administered VTRS1 was not as high as
that of RB51 but also increased over time, with 83% of vaccinates sero-positive for rough
Brucella antigens ten days following the fourth, and final, exposure. At no time were anti-OPS
antibodies detected in any of the vaccinates (Table 1). These data indicate that RB51 and
VTRS1 do stimulate host immune responses without interference with diagnostic tests; however,
more time may be required to mount a detectable humoral response when swine are orally
vaccinated. It is likely that blood samples collected several weeks following the final exposure
would yield a higher percentage of VTRS1 vaccinates seropositive for rough Brucella antigens.
Previous data collected by Edmonds et al in 2001 showed that SC administration of RB51
resulted in 50% of vaccinates mounting an immune response to rough Brucella antigens by day
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28 post-vaccination, but colonization of lymph nodes was not detected on days 14 or 28. In
contrast, all swine SC vaccinated with VTRS1 in the current study were seropositive for rough
Brucella antigens by day 24 post-vaccination and the vaccine transiently colonized the swine at
low numbers (<200 cfu/g) (Table 2).
A second group of swine were orally vaccinated with VTRS1 utilizing the pecan shell
and Karo syrup scarification mechanism developed by Edmonds et al. It was found that despite
the use of two logs less CFU than the RB51 vaccination in previous studies (Edmonds et al
2001), VTRS1 stimulated a higher immune response in a shorter period of time. Tissue
colonization by RB51 exceeded that of VTRS1; however, VTRS1 again displayed transient
colonization similar to that observed in SC vaccinates (Table 2).
Overall, SC and oral administration of VTRS1 resulted in comparable immune responses
in vaccinated swine and at no time did the vaccines stimulate the production of anti-OPS
antibodies. Lymph node colonization by the vaccine strain was somewhat delayed in oral as
compared to SC vaccinates; however, this may be due to the fact that oral exposure requires
more time for lymph node colonization localization. Extending the timeframe of this study may
offer a better explanation.
Serological testing performed on another set of gilts orally vaccinated with either VTRS1
or RB51 yielded similar immune response results to rough Brucella antigens. Eighty-nine
percent of VTRS1 vaccinates and 75% of RB51 vaccinates were serological responders
following four oral exposures to the vaccines without evidence of the formation of antibodies
specific for the OPS antigens of smooth Brucella (Table 6). These gilts were bred, challenged at
mid-gestation with virulent B. suis, and pregnancies were monitored until delivery. All groups,
including non-vaccinated saline controls, yielded a comparable average litter size, ranging
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between seven and nine piglets. VTRS1 vaccinates and saline control sows had a live birth rate
of 94% and 89%, respectively (Table 6). One RB51 vaccinated sow aborted her litter of eleven
piglets at approximately 14 weeks gestation. She was not in good health during her pregnancy,
apparently due to an abscess on her right hind leg. It is possible that her litter was aborted due to
this stress on her pregnancy, as none of the aborted piglets were culture positive for the challenge
strain. If her litter is not included in final calculations, 100% of the RB51 vaccinates’ litters
were born live. It seems that there is no significant difference in live birth rate in vaccinates as
compared to saline controls.
In 1995, Hagius et al performed a similar study evaluating the efficacy of orally
administered RB51 against virulent B. suis challenge. In that study it was found that RB51
vaccination resulted in fewer dead piglets and an increased litter size as compared to saline
controls. These results are supported by the present study, in which RB51 vaccinates farrowed
an average of eight piglets, as compared to seven piglets in saline controls, and if the aborted
litter is not included, 100% of piglets born to RB51 vaccinates were live.
Oral vaccination with both RB51 and VTRS1 were shown to provide approximately three
logs of protection against infection of the litter by virulent B. suis when the sows were
challenged at mid-gestation. The challenge strain was not recovered from any of the RB51
vaccinates’ litters, supporting research performed by Hagius et al (1995) and Lord et al (1998).
In 2001 the SC administration of VTRS1 was also evaluated in terms of its protection against
virulent challenge. None of the vaccinated sows aborted, and both litters and sows were
completely protected against virulent B. suis challenge (Hagius 2001). Oral vaccination with
VTRS1 was shown in the current study to offer less protection than SC vaccination, with 33% of
oral VTRS1 vaccinates’ litters colonized by the challenge strain at very low numbers (Table 7).
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Based on these culture results, it can be stated that the litters of sows orally vaccinated with
RB51 or VTRS1 were afforded significant protection against virulent B. suis challenge at midgestation.
Oral RB51 vaccination was not sufficient to protect sows against infection by virulent B.
suis when challenged at mid-gestation. All sows were culture positive for the challenge strain
four weeks post-parturition (Table 7), in agreement with research performed by Hagius et al in
2001. Lord et al found all RB51 vaccinated sows to be protected against virulent B. suis
challenge; however, only vaginal swabs were collected for bacteriological analysis (Lord et al
1998). In the current study uterine swabs taken of RB51 vaccinates at necropsy were all
negative for B. suis, supporting the findings of Lord et al; however, when lymph node
colonization was evaluated, 75% of vaccinated sows were positive for B. suis. While SC
administration of VTRS1 has been shown to provide 100% protection against virulent B. suis
(Hagius 2001), oral administration in the current study offered partial protection against sow
infection. Compared to saline controls, approximately one log of protection was observed in
orally vaccinated sows.
Based on these studies, orally administered VTRS1 has proven to be a more efficacious
vaccine for swine brucellosis than RB51. Immune responses to rough Brucella antigens appear
in a shorter period of time after vaccination with VTRS1 as compared to RB51, with transient
lymph node tissue colonization. Vaccinated sows were partially protected against virulent B.
suis challenge at mid-gestation, while RB51 vaccinated sows were not protected. Litters were
significantly protected against B. suis infection. The absence of anti-OPS antibody formation in
VTRS1 vaccinated swine indicates that this vaccine does not interfere with current brucellosis
diagnostic tests.
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Pseudorabies virus gD was chosen as a candidate for a potential subunit vaccine due to its
immunogenic properties. In mice, purified gD has been shown to stimulate the production of
virus-neutralizing antibodies (Ishii et al 1988) and protect against PRV infection (Haagmans et al
1999). Marchioli et al was able to administer gD via a recombinant vaccinia virus and provide
protection against lethal PRV infection in both mice and swine (Marchioli et al 1987), and Shiau
et al used live non-pathogenic E. coli as a delivery method to induce protective immune
responses against gD in mice (Shiau et al 2001). In order to create a multivalent vaccine for
PRV and brucellosis, the plasmid pBBgroE ssLgD, encoding for gD, was successfully
electroporated into RB51 and VTRS1 in the current study (Figure 1), yielding vaccine strains
RB51+gD and VTRS1+gD. These multivalent vaccines required an additional 48 hours for
appearance of colonies in the laboratory as compared to the parent strains.
Serological responses in swine SC vaccinated with RB51+gD were greater than RB51
vaccinates in previous studies performed by Edmonds et al in 2001. One hundred percent of
RB51+gD vaccinated swine were seropositive for rough Brucella antigens by day 24 (Table 3),
whereas only 50% of SC RB51 vaccinates were positive. At no point were antibodies specific
for the OPS antigens of smooth Brucella detected in any of the vaccinates. Lymph node
colonization by the vaccine strains was comparable in both RB51 and RB51+gD vaccinates,
yielding low numbers of the vaccine strains (Edmonds et al 2001).
Oral vaccination with RB51+gD yielded serological responses comparable to that
stimulated by oral administration of the parent strain, RB51, showing that the addition of the
pBBgroE ssLgD plasmid neither alters the stimulation of antibodies to rough Brucella antigens,
nor provokes immune responses to OPS antigens. Approximately two logs greater CFU was
used for the RB51 oral vaccination performed by Edmonds et al in 2001, which most likely
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explains the lower levels of tissue colonization present in RB51+gD vaccinated swine. It is also
possible that the slower growth in vitro of the transformed strain decreased the number of
colonized swine in this study. Extending the timeframe of the study in order to observe tissue
colonization over a longer period of time post-vaccination may allow for a clearer interpretation
of this data.
Both SC and oral vaccination with VTRS1+gD provided comparable stimulation of the
formation of antibodies against rough Brucella antigens as the parent strain VTRS1 without
stimulating the production of anti-OPS antibodies; however, VTRS1+gD was not recovered from
the lymph nodes of vaccinated swine until at least 24 days post-vaccination when administered
either orally or SC (Table 4). This delayed colonization may also be due to slower growth of the
transformed bacteria, and evaluation of lymph nodes beyond 31 days post vaccination may allow
for further clarification.
Previous studies have shown that gD stimulates humoral immune responses and the
formation of virus-neutralizing antibodies (Haagmans et al 1999, Ishii et al 1988), and when
administered via live vaccinia virus or E. coli, gD partially protected mice against virulent PRV
challenge (Marchioli et al 1987, Shiau et al 2001). In the current study, SC VTRS1+gD
vaccination provided the highest immune responses to PRV gD, with 66% of vaccinates seropositive for antibodies against PRV gD (Table 4). It is surprising that greater immune responses
were not detected in the current study; only 33% of SC RB51+gD vaccinates and 14% of oral
RB51+gD and VTRS1+gD vaccinates were sero-positive for antibodies against PRV gD (Tables
3 and 4). The low number of vaccinates forming antibodies to the plasmid protein may be linked
to the slower growth of the transformed vaccine strains.
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When administered to pregnant swine at mid-gestation, neither VTRS1+gD nor
RB51+gD were abortogenic, and the vaccine strains were not recovered from the sows or their
litters. Additionally, challenge with the transformed strains did not decrease litter size or the live
birth rate, as compared to saline controls (Table 5). Two logs greater CFU were used to
challenge sows with the vaccine strains due to their rough morphology and suspected attenuated
nature, and even with this increased dose, VTRS1+gD and RB51+gD were shown to be safely
administered to pregnant sows.
The efficacy of these vaccines has not yet been fully evaluated, as the final study is
ongoing; however, the serological responses of gilts vaccinated prior to breeding have been
examined. One hundred percent of gilts SC vaccinated with VTRS1+gD were seropositive for
rough Brucella antigens after two exposures without stimulating the production of antibodies
specific for the OPS antigens of smooth Brucella, and 78% possessed antibodies to the PRV gD.
The orally administered strains yielded lower immune responses than their parent strains, even
with a total of five exposures to the vaccines (Table 8). This is likely attributed to their slower
growth in the host as noted both in the laboratory and when lymph node colonization was
evaluated.
A concise evaluation of the use of RB51+gD and/or VTRS1+gD as vaccines against
brucellosis cannot be given until the efficacy study is complete; however, it appears that while
lymph node colonization is not as efficient as with the parent strains, serological responses to
rough Brucella antigens are not altered by the addition of the pBBgroE ssLgD plasmid, these
vaccines do not interfere with current brucellosis diagnostic tests by stimulating the formation of
anti-OPS antibodies, and both strains appear to be safe for use in pregnant swine.
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CHAPTER 6: SUMMARY
In this study it has been found that the rough attenuated mutant B. suis Strain VTRS1
stimulates host immune responses when administered either orally or SC to swine as well as
transiently colonizing lymph node tissues without interfering with current brucellosis diagnostic
techniques. The antibody production specific for rough Brucella antigens stimulated by VTRS1
vaccination surpasses that present in rough B. abortus Strain RB51 vaccinates. Additionally,
VTRS1 provides significant protection against litter infection when orally vaccinated sows are
challenged with virulent B. suis at mid-gestation. Both RB51 and VTRS1 vaccination provide
approximately three logs of protection against litter infection; however, unlike RB51, VTRS1
also provides the sows themselves with partial protection against virulent B. suis challenge.
These data support the conclusion that VTRS1 is a more efficacious vaccine than RB51 for
swine brucellosis and does not interfere with current brucellosis diagnostic techniques.
The addition of a plasmid encoding for PRV gD to both RB51 and VTRS1 has no
significant effect on the ability of these strains to stimulate humoral immune responses to rough
Brucella antigens in vaccinated swine and does not interfere with brucellosis diagnostic
techniques; however, despite the highly immunogenic nature of gD, low numbers of swine
produce detectable immune responses to this antigen as a result of oral or SC RB51+gD or
VTRS1+gD vaccination. Additionally, tissue colonization in RB51+gD and VTRS1+gD
vaccinated swine is significantly lower than that present in pigs vaccinated with the parent
strains. These observations can most likely be attributed to the slower growth of RB51+gD and
VTRS1+gD in the host. Future studies focusing on tissue colonization over longer periods of
time post-vaccination are necessary in order to determine the cause of this phenomenon.
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VTRS1+gD and RB51+gD do not cause abortion or infection of the sow or litter when
administered conjunctively to pregnant sows at mid-gestation, indicating that these vaccines are
safe for use in pregnant swine. Experiments evaluating the efficacy of RB51+gD and
VTRS1+gD against B. suis challenge are currently in progress. Based on the fact that no
decrease in immune response against rough Brucella antigens is observed following the addition
of the gD plasmid, sow and litter protection against challenge with virulent B. suis in RB51+gD
and VTRS1+gD vaccinated sows is expected to be equivalent to that afforded by the parent
strains.
Future studies are necessary in order to completely evaluate RB51+gD and VTRS1+gD
as multivalent vaccines for brucellosis and pseudorabies in swine. These vaccines must be
evaluated in terms of their efficacy against virulent PRV challenge in both sows and their litters,
as well as finding means to increase host immune responses to the gD antigen.
VTRS1 has proven to surpass RB51 in its ability to provoke vaccinates’ immune
responses without interfering with diagnostic tests for brucellosis as well as provide greater
protection against sow infection following mid-gestational challenge with virulent B. suis. The
addition of a plasmid encoding for PRV gD to RB51 and VTRS1 does not affect host immune
responses to rough Brucella antigens, though the formation of anti-PRV gD antibodies
stimulated by vaccination with RB51+gD and VTRS1+gD is lower than expected.
The feral swine reservoirs that harbor B. suis and PRV remain a constant threat to
domestic herds. A multivalent vaccine that could be administered orally to the feral swine
population as bait would greatly increase the success of brucellosis and pseudorabies eradication
programs, as well as protect domestic herds from infection. The efficacy of the vaccine strain B.
suis Strain VTRS1 and its lack of interference with current brucellosis diagnostic tests make it an
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excellent candidate for a swine brucellosis vaccine. The multivalent vaccine strains RB51+gD
and VTRS1+gD stimulate host immune responses to rough Brucella antigens and are safe for use
in pregnant swine. These strains are expected to demonstrate the same level of protection against
virulent B. suis challenge observed in parent strains RB51 and VTRS1; however immune
responses to PRV gD in vaccinated swine and the efficacy of RB51+gD and VTRS1+gD against
virulent PRV challenge in pregnant swine must further be evaluated prior to their use as
multivalent vaccines.
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